Design, Synthesis and Antidiabetic Activity of Novel Pyrrole‐3‐Carboximidamide Derivatives as Dipeptidyl Peptidase‐4 Inhibitors
Archiv der Pharmazie · 2025
DOI: 10.1002/ardp.70077 ↗Kurz gefasst
Fachartikel in der Zeitschrift Archiv der Pharmazie, 2025. Verfasst von Hossein Fasihi Dastjerdi und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Chemistry, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran. Hauptthemen laut MEDLINE: Dipeptidyl-Peptidase IV Inhibitors, Hypoglycemic Agents, Drug Design, Diabetes Mellitus, Experimental. Die Arbeit nennt 27 Literaturangaben. Gefördert von: This study was supported by the research council of the School of Pharmacy, Shahid Beheshti University of Medical Sciences. [Grant No. 24008]..
Abstract (Originalsprache)
Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance and impaired insulin secretion, and dipeptidyl peptidase‐4 (DPP‐4) inhibitors have emerged as an effective therapeutic option. A new series of pyrrole‐3‐carboximidamide derivatives was designed, synthesized, and evaluated as DPP‐4 inhibitors. Most of the synthesized compounds exhibited favorable inhibitory activity against the DPP‐4 enzyme, and compounds 5f and 5g were found to be the most potent inhibitors with IC₅₀ values of 12.19 and 23.08 nM, respectively. In vivo studies in diabetic Wistar rats showed that daily administration of compound 5g for 2 weeks resulted in a significant decrease in blood glucose compared with the control group. Moreover, compound 5g was effective in reducing plasma glucose in an acute oral glucose tolerance test in NMRI mice. The antiglycemic effects of compound 5g were comparable with standard treatment by sitagliptin, with no effect on normoglycemic rats. Both the in vitro and in vivo antidiabetic properties suggest that compound 5g could be considered a promising candidate for development as an antidiabetic medication.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical Chemistry, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
- Department of Pharmacology and Toxicology, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
- Department of Biophysics, Faculty of Biological Sciences, Tarbiat Modares University, Tehran, Iran.
- Central Research Laboratories, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
ORCID-Profile: Sayyed Abbas Tabatabai
Förderung
- This study was supported by the research council of the School of Pharmacy, Shahid Beheshti University of Medical Sciences. [Grant No. 24008].
Zitieren
APA
Dastjerdi, H. F., Naderi, N., Garmabdari, A., Nematpour, M., Ebrahimi, M., Hosseinpoor, S., Saberinasab, F., Sheikholislam, Z., Hosseini, O., Rezaee, E., & Tabatabai, S. A. (2025). Design, Synthesis and Antidiabetic Activity of Novel Pyrrole‐3‐Carboximidamide Derivatives as Dipeptidyl Peptidase‐4 Inhibitors. Archiv der Pharmazie. https://doi.org/10.1002/ardp.70077
Vancouver
Dastjerdi HF, Naderi N, Garmabdari A, Nematpour M, Ebrahimi M, Hosseinpoor S, et al. Design, Synthesis and Antidiabetic Activity of Novel Pyrrole‐3‐Carboximidamide Derivatives as Dipeptidyl Peptidase‐4 Inhibitors. Archiv der Pharmazie. 2025. doi:10.1002/ardp.70077
BibTeX
@article{Dastjerdi2025,
author = {Dastjerdi, Hossein Fasihi and Naderi, Nima and Garmabdari, Amir and Nematpour, Manijeh and Ebrahimi, Melika and Hosseinpoor, Samaneh and Saberinasab, Fatemeh and Sheikholislam, Zahra and Hosseini, Omid and Rezaee, Elham and Tabatabai, Sayyed Abbas},
title = {Design, Synthesis and Antidiabetic Activity of Novel Pyrrole‐3‐Carboximidamide Derivatives as Dipeptidyl Peptidase‐4 Inhibitors},
journal = {Archiv der Pharmazie},
year = {2025},
doi = {10.1002/ardp.70077}
}
EUVIMED